Condition: HER2-positive Breast Cancer · Sponsor: National Cancer Center, Japan
This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
This description comes directly from the study's public registry record.
Yuki Kojima, MD, PhD · 0335422511 · yuukojim@ncc.go.jp
Always discuss trial participation with your own doctor first.
| National Cancer Center Hospital, Japan | Chuo-ku, Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05433753